

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	3,116,282	12/31/63	Hunter	
	A02	3,480,613	11/25/69	Walton	
	A03	3,891,623	06/24/75	Vorbruggen, et al.	
	A04	4,022,889	05/01/77	Bannister et al.	
	A05	4,058,602	11/01/77	Beisler et al.	
	A06	4,209,613	06/24/80	Vorbruggen, et al.	
	A07	4,239,753	12/01/80	Skulnick et al.	
	A08	4,294,766	10/13/81	Schmidt, et al.	
	A09	4,605,659	08/12/86	Verheyden, et al.	
	A10	4,689,404	08/25/87	Kawada, et al.	
	A11	4,754,026	06/28/88	Kawada, et al.	
	A12	4,814,477	03/21/89	Wijnberg, et al.	
	A13	4,880,784	11/14/89	Robins, et al.	
	A14	4,952,740	08/28/90	Juge, et al.	
	A15	5,034,394	07/23/91	Daluge	
	A16	5,122,517	06/16/92	Vince, et al.	
	A17	5,200,514	04/06/93	Chu	
	A18	5,246,924	09/01/93	Fox, et al.	
	A19	5,256,797	10/26/93	Chou, et al.	
	A20	5,322,955	06/21/94	Matsumoto, et al.	
	A21	5,371,210	12/06/94	Chou, et al.	
	A22	5,391,769	02/21/95	Matsumoto, et al.	
	A23	5,401,861	03/28/95	Chou, et al.	
	A24	5,463,092	10/31/95	Hostetler, et al.	
	A25	5,539,116	07/23/96	Liotta, et al.	
	A26	5,565,438	10/15/96	Chu, et al.	
	A27	5,567,688	10/22/96	Chu, et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28	5,587,362	12/24/96	Chu, et al.	
	A29	5,606,048	02/25/97	Chou, et al.	
	A30	5,696,277	12/09/97	Hostetler, et al.	
	A31	5,744,600	04/28/98	Mansuri, et al.	
	A32	5,750,676	05/12/98	Vorbruggen, et al.	
	A33	5,763,418	06/09/98	Matsuda, et al.	
	A34	5,780,617	07/14/98	Van den Bosch, et al.	
	A35	5,789,608	08/04/98	Glazier	
	A36	5,821,357	10/13/98	Chou, et al.	
	A37	5,977,325	11/02/99	McCarthy, et al.	
	A38	6,002,029	12/14/99	Hostetler, et al.	
	A39	6,063,628	05/16/00	Loeb, et al.	
	A40	6,140,310	10/31/00	Glazier	
	A41	6,153,594	11/28/00	Borretzen, et al.	
	A42	6,156,501	12/05/00	McGall, et al.	
	A43	6,172,046	01/09/01	Albrecht	
	A44	6,248,878	06/19/01	Matulic-Adamic, et al.	
	A45	6,252,060	06/26/01	Hostetler	
	A46	6,271,212	08/07/01	Chu, et al.	
	A47	6,277,830	08/21/01	Ganguly, et al.	
	A48	6,348,587	02/19/02	Schinazi, et al.	
	A49	6,369,040	04/09/02	Acevedo, et al.	
	A50	6,436,437	08/20/02	Yatvin, et al.	
	A51	6,448,392	09/10/02	Hostetler, et al.	
	A52	6,455,508	09/24/02	Ramasamy, et al.	
	A53	6,458,772	10/01/02	Zhou, et al.	
	A54	6,458,773	10/01/02	Gosselin, et al.	

LA1-3017173v1

EXAMINER  
SIGNATURE

/Louise Humphrey/

DATE CONSIDERED

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

* Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A55	6,472,373	10/29/02	Albrecht	
	A56	6,495,677	12/17/02	Ramasamy, et al.	
	A57	6,566,344	05/20/03	Gosselin, et al.	
	A58	6,566,365	05/20/03	Storer	
	A59	6,569,837	05/27/03	Gosselin, et al.	
	A60	6,573,248	06/03/03	Ramasamy, et al.	
	A61	6,596,700	07/22/03	Sommadossi, et al.	
	A62	6,599,887	07/29/03	Hostetler, et al.	
	A63	6,605,614	08/12/03	Bachand, et al.	
	A64	6,642,206	11/01/03	Ramasamy et al.	
	A65	6,660,721	12/09/03	Devos, et al.	
	A66	6,748,161	06/08/04	Ko, et al.	
	A67	6,752,981	06/22/04	Erion, et al.	
	A68	6,777,395	08/17/04	Bhat, et al.	
	A69	6,784,161	08/31/04	Ismaili, et al.	
	A70	6,784,166	08/31/04	Devos, et al.	
	A71	6,787,526	09/07/04	Bryant, et al.	
	A72	6,812,219	11/02/04	LaColla, et al.	
	A73	6,815,542	11/09/04	Hong, et al.	
	A74	6,831,069	12/14/04	Tam, et al.	
	A75	6,833,361	12/21/04	Hong, et al.	
	A76	6,846,810	01/25/05	Martin, et al.	
	A77	6,875,751	04/05/05	Imbach, et al.	
	A78	6,908,924	06/21/05	Watanabe, et al.	
	A79	6,911,424	06/28/05	Schinazi, et al.	
	A80	6,914,054	07/05/05	Sommadossi, et al.	
	A81	6,927,291	08/09/05	Jin, et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A82	6,946,115	09/20/05	Erion, et al.	
	A83	6,946,450	09/20/05	Gosselin, et al.	
	A84	6,949,522	09/27/05	Otto, et al.	
	A85	6,965,033	11/15/05	Jiang, et al.	
	A86	6,965,066	11/15/05	Jiang, et al.	
	A87	7,056,895	06/06/06	Ramasamy, et al.	
	A88	7,094,770	08/22/06	Watanabe, et al.	
	A89	7,101,861	09/05/06	Sommadossi, et al.	
	A90	7,105,493	09/12/06	Sommadossi, et al.	
	A91	7,105,499	09/12/06	Carroll, et al.	
	A92	7,125,855	10/24/06	Bhat, et al.	
	A93	7,144,868	12/05/06	Roberts, et al.	
	A94	7,148,206	12/12/06	Sommadossi, et al.	
	A95	7,151,089	12/19/06	Roberts, et al.	
	A96	7,157,434	01/02/07	Keicher, et al.	
	A97	7,157,441	01/02/07	Sommadossi, et al.	
	A98	7,163,929	01/16/07	Sommadossi, et al.	
	A99	7,169,766	01/30/07	Sommadossi, et al.	
	A100	7,202,224	04/10/07	Eldrup, et al.	
	A101	10/845,976	05/14/04	Storer, et al.	
	A102	11/005,443	12/06/04	Gosselin, et al.	
	A103	11/516,928	09/06/06	Sommadossi, et al.	
	A104	11/644,304	12/22/06	Mayes, et al.	
	A105	2002/0019363	02/14/02	Ismaili, et al.	
	A106	2002/0035085	03/21/02	Sommadossi, et al.	
	A107	2002/0052345	05/02/02	Erion, et al.	
	A108	2002/0055473	05/09/02	Ganguly, et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

* Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A109	2002/0055483	05/09/02	Watanabe, et al.	
	A110	2002/0095033	07/18/02	Ramasamy et al.	
	A111	2002/0099072	07/25/02	Bachand, et al.	
	A112	2002/0127203	09/12/02	Albrecht	
	A113	2002/0156030	10/24/02	Ramasamy et al.	
	A114	2002/0173490	11/21/02	Jiang, et al.	
	A115	2002/0198171	12/26/02	Schinazi, et al.	
	A116	2003/0039630	02/27/03	Albrecht	
	A117	2003/0053986	03/20/03	Zahm	
	A118	2003/0055013	03/20/03	Brass	
	A119	2003/0083306	05/01/03	Imbach, et al.	
	A120	2003/0087873	05/08/03	Stuyver, et al.	
	A121	2003/0124512	07/03/03	Stuyver	
	A122	2003/0220290	11/27/03	Gosselin, et al.	
	A123	2003/0225028	12/04/03	Gosselin, et al.	
	A124	2003/0225029	12/04/03	Stuyver	
	A125	2003/0225037	12/04/03	Storer, et al.	
	A126	2003/0236216	12/25/03	Devos, et al.	
	A127	2004/0002476	01/01/04	Stuyver et al.	
	A128	2004/0002596	01/01/04	Hong, et al.	
	A129	2004/0006002	01/08/04	Sommadossi, et al.	
	A130	2004/0023921	02/05/04	Hong, et al.	
	A131	2004/0059104	03/25/04	Cook, et al.	
	A132	2004/0063622	04/01/04	Sommadossi, et al.	
	A133	2004/0063658	04/01/04	Roberts et al.	
	A134	2004/0067901	04/08/04	Bhat et al.	
	A135	2004/0072788	04/15/04	Bhat et al.	

LA1-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number -- Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A136	2004/0077587	04/22/04	Sommadossi, et al.	
	A137	2004/0097461	05/20/04	Sommadossi, et al.	
	A138	2004/0097462	05/20/04	Sommadossi, et al.	
	A139	2004/0101535	05/27/04	Sommadossi, et al.	
	A140	2004/0102414	05/27/04	Sommadossi, et al.	
	A141	2004/0110717	06/10/04	Carroll, et al.	
	A142	2004/0110718	06/10/04	Devos, et al.	
	A143	2004/0121980	06/24/04	Martin, et al.	
	A144	2004/0147464	07/29/04	Roberts, et al.	
	A145	2004/0229839	11/18/04	Babu, et al.	
	A146	2004/0248844	12/09/04	Ismaili, et al.	
	A147	2004/0259934	12/23/04	Olsen, et al.	
	A148	2004/0266722	12/30/04	Devos, et al.	
	A149	2004/0266723	12/30/04	Otto, et al.	
	A150	2004/0266996	12/30/04	Microbiologica Quimica E Farmaceutica Ltd., Brazil	
	A151	2005/0009737	01/13/05	Clark, et al.	
	A152	2005/0020825	01/27/05	Storer, et al.	
	A153	2005/0031588	02/10/05	Sommadossi, et al.	
	A154	2005/0038240	02/17/05	Connolly, et al.	
	A155	2005/0090463	04/28/05	Roberts, et al.	
	A156	2005/0101550	05/12/05	Roberts, et al.	
	A157	2005/0107312	05/19/05	Keicher, et al.	
	A158	2005/0113330	05/26/05	Imbach, et al.	
	A159	2005/0119200	06/02/05	Roberts, et al.	
	A160	2005/0124532	06/09/05	Sommadossi, et al.	
	A161	2005/0137141	06/23/05	Hilfinger, et al.	

LAI-3017173v1

EXAMINER  
SIGNATURE

/Louise Humphrey/

DATE CONSIDERED

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A162	2005/0137161	06/23/05	Sommadossi, et al.	
	A163	2005/0215511	09/29/05	Roberts, et al.	
	A164	2006/0040890	03/23/06	Martin, et al.	
	A165	2006/0111311	05/25/06	Keicher, et al.	
	A166	2006/0166865	07/27/06	Sommadossi, et al.	
	A167	2006/0194835	08/31/06	Dugourd, et al.	
	A168	2006/0199783	09/01/06	Wang, et al.	
	A169	2006/0241064	10/26/06	Roberts, et al.	
	A170	2007/0015905	01/18/07	LaColla, et al.	
	A171	2007/0060503	03/15/07	Gosselin, et al.	
	A172	2007/0060504	03/15/07	Gosselin, et al.	
	A173	2007/0203334	08/30/07	Mayes, et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	CA 2252144	04/16/00	Miller, et al.		
	B02	DD 140254	02/20/80	Barwolff, et al.		
	B03	DE 102005012681	09/21/06	Weber, Lutz		
	B04	DE 1919307	01/14/71	Niedballa, et al.		
	B05	DE 2122991	11/16/72	Vorbruggen, et al.		
	B06	DE 2508312	09/02/76	Vorbruggen, et al.		
	B07	DE 4224737	02/03/94	Schott		
	B08	EP 0288847	04/16/88	Dobler, et al.		
	B09	EP 0352248	01/24/90	Medvir AB		
	B10	EP 0494119	01/03/92	Belleau, et al.		

LAJ-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B11	EP 0526655	02/10/93	Japan Tobacco Inc.		
	B12	EP 0553358	08/04/93	Japan Tobacco Inc.		
	B13	EP 0587364	03/16/94	Britton, et al.		
	B14	EP 0742287	11/13/96	McGall, et al.		
	B15	EP 0747389	12/11/96	Taiho Pharmaceutical Co Ltd		
	B16	FR 1581628	09/19/69	Merck & Co. Inc.		
	B17	GB 1163102	09/04/69	Merck & Co. Inc.		
	B18	GB 1187824	05/02/66	Walton		
	B19	GB 1542442	03/21/79	Schering AG		
	B20	GB 924246	04/24/63	Wellcome Foundation, Ltd.		
	B21	GB 984877	03/03/65	Zellstofffabrik Waldhof		
	B22	JP 02091022	03/30/90	Univ. of Minnesota		
	B23	JP 06135988	05/17/94	Toagosei Chemical Ind., Ltd.		
	B24	JP 06211890	08/02/94	Yamasa Shoyu Co. Ltd.		
	B25	JP 06228186	08/16/94	Yamasa Shoyu Co., Ltd.		
	B26	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho		
	B27	JP 09059292	03/04/97	Yamasa Shoyu Co. Ltd.		
	B28	JP 48048495	09/21/71	Kojin Co. Ltd.		
	B29	JP 61212592	09/20/86	Tokyo Tanabe Co. Ltd.		
	B30	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.		
	B31	JP 61263996	11/21/86	Boryung Pharmaceutical Co. Ltd.		
	B32	JP 63215694	09/08/88	Yamasa Shoyu Co. Ltd.		
	B33	JP 71021872	03/30/68	Sankyo Co., Ltd.		
	B34	WO 00/025799	05/11/00	Gosselin, et al.		
	B35	WO 01/032153	10/05/08	Biochem Pharma		
	B36	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B37	WO 01/068663	09/20/01	Ribapharm Corp.		

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./



**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B38	WO 02/003997	01/17/02	Ribapharm, Inc. or ICN Pharmaceuticals?		
	B39	WO 03/039523	05/15/03	Wengel		
	B40	WO 03/051899	06/26/03	Ribapharm Inc.		
	B41	WO 03/061576	07/31/03	Ribapharm Inc.		
	B42	WO 03/062256	07/31/03	Ribapharm Inc.		
	B43	WO 03/062257	07/31/03	Ribapharm Inc.		
	B44	WO 03/063771	08/07/03	Pharmasset Inc.		
	B45	WO 03/068162	08/21/03	Pharmasset Inc.		
	B46	WO 03/068164	08/21/03	Pharmasset Inc.		
	B47	WO 03/068244	08/21/03	Merck & Co.; Isis Pharmaceuticals Inc.		
	B48	WO 03/072757	09/04/03	Biota Inc.		
	B49	WO 03/081899	06/26/03	Ribapharm Inc.		
	B50	WO 03/093290	11/13/03	Genelabs Technologies Inc.		
	B51	WO 03/099840	12/04/03	Eldrup, et al.		
	B52	WO 03/100017	12/04/03	Eldrup, et al.		
	B53	WO 03/105770	12/24/03	Eldrup		
	B54	WO 03/106577	12/24/03	Weikard, et al.		
	B55	WO 04/000858	12/31/03	Merck & Co. Isis Pharmaceuticals		
	B56	WO 04/007512	01/22/04	Merck & Co. Isis Pharmaceuticals		
	B57	WO 04/023921	03/25/04	Kim		
	B58	WO 04/028481	04/08/04	Genelabs Technologies, Inc.		
	B59	WO 04/041203	05/21/04	Xenoport, Inc.,		
	B60	WO 04/043977	05/27/04	Prakush, et al.		
	B61	WO 04/043978	05/27/04	Baker, et al.		
	B62	WO 04/044132	05/27/04	Baker, et al.		
	B63	WO 04/046159	06/03/04	F. Hoffmann-La Roche AG		

LAI-301713v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B64	WO 04/046331	06/03/04	Idenix Cayman Limited		
	B65	WO 04/052899	06/24/04	Idenix Cayman Limited		
	B66	WO 04/058792	07/15/04	Idenix Cayman Limited		
	B67	WO 04/065398	08/05/04	Ribapharm, Inc.		
	B68	WO 04/072090	08/26/04	Merck & Co., Inc.		
	B69	WO 04/080466	09/23/04	Ribapharm, Inc.		
	B70	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B71	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B72	WO 04/106356	12/09/04	Syddansk Universitet		
	B73	WO 05/003147	01/13/05	Pharmasset, Ltd.		
	B74	WO 05/012327	02/10/05	University College Cardiff Consultants Limited		
	B75	WO 05/020884	03/10/05	CENT NAT RECH SCI.		
	B76	WO 05/020885	03/10/05	Isis Pharmaceuticals, Inc.		
	B77	WO 05/021568	03/10/05	Biota, Inc.		
	B78	WO 05/030258	04/07/05	Dihedron Corp.		
	B79	WO 05/042556	05/12/05	Genelabs Technologies, Inc.,		
	B80	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B81	WO 06/002231	01/05/06	Biocryst Pharmaceuticals, Inc.		
	B82	WO 06/012078	02/02/06	Merck & Co., Inc.		
	B83	WO 06/012440	02/02/06	Wang, et al.		
	B84	WO 06/016930	02/16/06	Intermune, Inc.		
	B85	WO 06/037028	04/06/06	CENT NAT RECH SCI		
	B86	WO 06/037227	04/13/06	Migenix Inc., Can.		
	B87	WO 06/063717	06/22/06	Universitaet Karlsruhe		
	B88	WO 06/065335	06/22/06	Merck & Co. Inc.,		
	B89	WO 06/097323	09/21/06	Weber, Lutz		

LA1-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B90	WO 06/100087	09/28/06	Novartis A.G.		
	B91	WO 06/121820	11/16/06	Valeant Research & Development		
	B92	WO 06/130532	12/07/06	Novartis AG, Switz.		
	B93	WO 07/011777	01/25/07	Novartis A.-G., Switz.		
	B94	WO 07/025304	01/03/07	University of Oxford; Idenix Pharmaceuticals; et al.		
	B95	WO 92/015308	09/17/92	Wellcome Foundation, Ltd.		
	B96	WO 92/018517	10/29/92	Cheng, et al.		
	B97	WO 94/001117	01/20/94	Koszalka, et al.		
	B98	WO 98/016184	04/23/98	ICN Pharmaceuticals		
	B99	WO 99/023104	05/14/99	Klecker, et al.		
	B100	WO 99/052514	10/21/99	Eli Lilly and Co.		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	AFDHAL, et al., Enhanced antiviral efficacy for valopicitabine plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection. <i>Journal of Hepatology</i> 2005, Vol. 42, Supplement 2, p. 39-40.	
	C02	ALTMANN, et al., The Effects of 2'- and 3'-Alkyl Substituents on Oligonucleotide Hybridization and Stability, <i>Biorganic &amp; Medicinal Chemistry Letter</i> , 1994, 4, No. 16, 1969-74.	
	C03	AWANO, et al., "Nucleosides and Nucleotides, Part 144 Synthesis and Antiviral Activity of 5-Substituted (2'-s)-2'-Deoxy-2'-C-Methylcytidines and -Uridines," <i>Archiv Der Pharmazie</i> , VCH Verlagsgesellschaft MbH, Weinheim, DE, vol. 329, February 1, 1996, (1996-02-01), pp. 66-72.	
	C04	BEIGELMAN et al., "New synthesis of 2'-C-methyl/nucleosides starting from D-glucose and D-ribose" <i>Carbohydrate Res.</i> , 1987, 166, 219-232	
	C05	BEIGELMAN et al., "Functionally complete analogs of nucleosides. The use of D-glucose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. <i>Biorganicheskaya Khimiya</i> , 1986, Vol. 12(10), pp. 1359-65.	
	C06	BHOPALE, Girish Mahadocar, et al., "Emerging drugs for chronic hepatitis C," <i>Hepatology Research</i> (2005), 32(3), 146-153.	
	C07	BIANCO A., et al., "Synthesis of a New Carbocyclic Nucleoside Analog," <i>Tetrahedron Letters</i> , 38(36):6433-6436, 1997	
	C08	BILLICH, et al., "Nucleoside Phosphotransferase from Malt Sprouts." <i>Biol. Chem. Hoppe-Seyler</i> . Vol. 367, pp. 267-278, April 1986.	

LAI-3017173v1

**EXAMINER SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C09	BIO, et al., "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor." <i>Journal of Organic Chemistry</i> (2004), 69(19), 6257-6266.	
	C10	BLOCH A., et al., "The Role of the 5'-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," <i>J. Med. Chem.</i> , 10(5):908-12 (September 1967).	
	C11	BRYANT M.L., et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," <i>Antimicrobial Agents and Chemotherapy</i> , 45(1):229-235 (January 2001).	
	C12	CAPPELLACCI, et al., "Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." <i>Journal of Medicinal Chemistry</i> (2005), 48(5), 1550-1562.	
	C13	CAPPELLACCI, et al., "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1'-C-methyl denosine analogues," <i>J. Med. Chem.</i> , vol. 45, 2002, pp. 1196-1202.	
	C14	CARROLL, S.S., "Nucleoside analog inhibitors of hepatitis C virus replication," <i>Infectious Disorders: Drug Targets</i> (2006), 6(1), 17-29.	
	C15	CARROLL S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," <i>J. Biol. Chem.</i> , 278(14): 11979-11984 (2003).	
	C16	CAVELIER, F., et al., "Studies of Selective Boc Removal in the Presence of Silyl Ethers," <i>Tetrahedron Letters</i> , 37: 5131-5134 (1996).	
	C17	CHAND, Pooran; et al., "Synthesis of (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." <i>Collection Symposium Series</i> (2005), 7( <i>Chemistry of Nucleic Acid Components</i> ), 329-332.	
	C18	CHEN <i>et al.</i> , <i>Heterocycles</i> , vol. 28, no. 2, 1989, pp.593-601	
	C19	CHIACCHIO, et al., "Stereoselective synthesis of 2'-amino-2',3'-dideoxynucleosides by nitrene 1,3-dipolar cycloaddition: A new efficient entry toward d4T and its 2-methyl analogue," <i>J. Org. Chem.</i> , vol. 64, 1999, pp. 28-36.	
	C20	CHIARAMONTE, et al., "Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophates." <i>Biochemistry</i> 2001, 40, 14260-14267.	
	C21	CLARK, et al., "Synthesis and antiviral activity...", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 16, 2006, 1712-1715.	
	C22	CLARK, et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." <i>Journal of Medicinal Chemistry</i> (2005), 48(17), 5504-5508.	
	C23	COELMONT, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine." <i>Antimicrobial Agents and Chemotherapy</i> (2006), 50(10), 3444-3446.	
	C24	COOK, G.S., "Improving the treatment of hepatitis C infection in the UK," <i>Expert Opinion on Pharmacotherapy</i> , (2007) Vol. 8, No. 2, pp. 183-191.	
	C25	CORNBERG, M., et al., "Present and future therapy for hepatitis C virus," <i>Expert review of Anti-Infective Therapy</i> , (2006) Vol. 4, No. 5, pp. 781-793.	
	C26	CRETTON-SCOTT, E., et al., "Pharmacokinetics of B-L-2'-Deoxycytidine Prodrugs in Monkeys," <i>Antiviral res.</i> , 50:A44 (2001).	
	C27	CZERNECKI, S., et al., "Synthesis of 2'-deoxy-2'-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase," <i>Can. J. Chem.</i> , vol. 71, 1993, pp. 413-416.	
	C28	DALPIAZ, et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." <i>European Journal of Pharmacology</i> (2002), 448(2-3), 123-131	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered. whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C29	DANIELS et al., "Tautomerism of Uracil and Thymine in Aqueous Solution: Spectroscopic Evidence", Proc. Nat. Acad. Sci. USA, Vol. 69, no. 9, pp. 2488-2491, 1972.	
	C30	DAVIS, G.L., "New Therapies: Oral Inhibitors and Immune Modulators," Clinics in Liver Disease, (2006) Vol. 10, No. 4, pp. 867-880.	
	C31	DAVISSON, V.J. et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," J. Org. Chem., 52(9):1794-1801 (1987).	
	C32	DING, et al., "Synthesis of 2'-b-C-methyl toycamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727.	
	C33	DING, et al., "Synthesis of 9-(2-b-C-methyl-b-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 709-713	
	C34	DUTARTRE, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," Antimicrobial Agents and Chemotherapy, (2006) Vol. 50, No. 12, pp. 4161-4169.	
	C35	ELDRUP et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(21), 5284-5297.	
	C36	ELDRUP, et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase.", Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(9), 2283-2295.	
	C37	FARQUHAR et al., "Biologically reversible phosphate-protective groups," J. Pharm. Sci., 1983, 72(3): 324	
	C38	FEAST, A.A.J., et al., "Studies on the D-Glucosaccharinic Acids," Acta Chemica Scandinavica 19(5):1127-1134 (1965).	
	C39	FOX, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," J. Am. Chem. Soc., 81: 178-187 (January 5, 1959).	
	C40	FRANCESCO, et al. Antiviral Research 58 (2003) 1-16	
	C41	FRANCHETTI, et al., "Antitumor Activity of C-Methyl-b-D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors." Journal of Medicinal Chemistry (2005), 48(15), 4983-4989.	
	C42	FUJIMORI, et al., "A Convenient and Stereoselective Synthesis of 2'-Deoxy-[beta]-L-nucleosides," Nucleosides & Nucleotides, 11(2-4), 341-349 (1992); only CAPLUS abstract supplied.	
	C43	FURUKAWA, Y., et al., "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," Chem. Pharm. Bull., 16(6):1076-1080 (June 1968).	
	C44	GALLO, et al., "2'-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2'-hydroxyl Group." Tetrahedron, 57 (2001), 5707-5713.	
	C45	GEROTTO, et al., Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in non-responder patients with chronic hepatitis C. Journal of Virology, September 1999, Vol. 73, No. 9, pp. 7241-7247.	
	C46	GIRADET, et al., "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." Journal of Medicinal Chemistry (2000), 43(20), 3704-3713.	
	C47	GRETTCH, D.R., "Use and interpretation of HCV diagnostic tests in the clinical setting." Clinics in Liver Disease, November 1997, Vol. 1, No. 3, pp. 547-557.	
	C48	GROUILLER et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." J. Pharm.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Belg., 47(4), 381-3 (1992).	
	C49	GRUNNAGEL, et al., "Preparation of D-Tagatose." Justus Liebigs Annalen der Chemie (1969), 721: 234-5.	
	C50	HASSAN, et al., "Nucleosides and Nucleotides 151: Conversion of (Z)-2'-Cyanomethylene-2'-Deoxyuridines into their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions." J. Org. Chem., vol. 61, 1996, pp. 6261-6267.	
	C51	HASSAN, et al., "Nucleosides and Nucleotides 156: Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophenol Addition Reactions at the 2'-Position of 2'-[(Alkoxycarbonyl)methylene]-2'-deoxyuridines: Conversion of (Z)-2'-[(Alkoxycarbonyl)methylene]-2'-Deoxyuridines into their (E)-Isomers" J. Org. Chem., vol. 62, 1997, pp. 11-17.	
	C52	HATTORI, H. et al., "Nucleosides and Nucleotides 158" <i>Journal of Medicinal Chemistry. American Chemical Society</i> , Vol. 39, 1996, pp. 5005-5001	
	C53	HAYAKAWA, et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2'- and 3'-positions." <i>Chemical &amp; Pharmaceutical Bulletin</i> (1987), 35(6), 2605-8.	
	C54	HOARD, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," <i>J. Am Chem. Soc.</i> , 87(8):1785-1788 (April 20, 1965).	
	C55	HODGE, et al., "Amadori Rearrangement Products." <i>Methods in Carbohydrate Chemistry</i> (1963), 2: 99-107.	
	C56	HOLY, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides to the Pyrimidine Series," <i>Collect. Czech. Chem. Commun.</i> , 37(12): 4072-4087 (1972).	
	C57	HOSSAIN, et al., "Synthesis of 2'- and 3'-Spiro-isoxazolidine Derivatives of Thymidine & Their Conversions to 2',3'-dideoxy-2', 3'-dideoxy-3'-C-substituted nucleosides by Radical Promoted Fragmentation," <i>Tetrahedron</i> Vol. 49, No. 44, pp. 10133-10156, (1993).	
	C58	HU, et al., "Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection." <i>Journal of Viral Hepatitis</i> , 2001, Vol. 8, p. 1-18.	
	C59	IGLESIAS, et al., "Complete and Regioselective Deacetylation of Peracetylated Uridines Using a Lipase." <i>Biotechnology Letters</i> 22: 361-365, 2000.	
	C60	IMORI, et al., "2'-C-, 3'-C-, and 5'-C-Methylsanguivamycins: conformational lock with the methyl group." <i>Tetrahedron Letters</i> (1991), 32(49), 7273-6.	
	C61	IMORI, et al., "A study on conformationally restricted sanguivamycins and their inhibitory abilities of protein kinases." <i>Nucleic Acids Symposium Series</i> (1992), 27(Nineteenth Symposium on Nucleic Acids Chemistry, 1992), 169-70.	
	C62	KEGASHIRA, K., et al., "Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," <i>Journal of Medicinal Chemistry</i> , (30 Nov 2006) Vol. 449, No. 24, pp. 6950-6953.	
	C63	IMAI, K., et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." <i>J. Org. Chem.</i> , 34(6): 1547-1550 (June 1969).	
	C64	KAKEFUDA, et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethyl-1-b-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." <i>Tetrahedron</i> (1993), 49(38), 8513-28	

LA1-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C65	KAMAIKE, K., et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine, [6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nucleosides and Nucleotides, 15(1-3): 749-769 (1996).	
	C66	KANEKO, M., et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20:1050-1053 (1972).	
	C67	KEMPE, T., et al., "Selective 2'-Benzoylation at the Cis 2', 3'-diols of Protected Ribonucleosides. New Solid Phase Synthesis of RNA and DNA-RNA Mixtures," Nucleic Acids Res., 10(21):6695-6714 (November 11, 1982).	
	C68	KERR, S.G., et al., "N-(Dialkylamino)Methylene Derivatives of 2'-Deoxycytidine and Arabinocytidine: Physicochemical Studies for Potential Prodrug Applications," J. Pharm. Sci., 83(4): 582-586 (April 1994).	
	C69	KIM, et al., "A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein," Molecular Pharmaceutics (2004), 1(2), 117-127.	
	C70	KLUMPP, et al., "The Novel Nucleoside Analog R1479 (4'-Azidocytidine) is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture," The Journal of Biological Chemistry, Vol. 281, No. 7, pp. 3793-3799, February 17, 2006.	
	C71	KOHN, et al., "A new method for the synthesis of furanose derivatives of aldohexoses," J. Am. Chem. Soc., 1965, 87(23): 5475-80.	
	C72	KOTRA, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2', 2'-difluoro-L-erythro-pentofuranosyl Nucleosides," J. Med. Chem. 1997, 40, 3635-3644.	
	C73	KUHN, R., et al., "Über eine molekulare Umlagerung von N-Glucosiden," Jahrg. 69, 1936, p. 1745-1754.	
	C74	LANDOWSKI, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics (2006), 316(2), 572-580.	
	C75	LE POGAM, et al., "In Vitro Selected Con1 Subgenomic Replicons Resistant to 2'-C-Methyl-Cytidine or to R1479 Show Lack of Cross Resistance," Virology 351 (2006), 349-359.	
	C76	LE POGAM, et al., "Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus," Journal of Virology, Vol. 80, No. 12, June 2006, p. 6146-6154.	
	C77	LI, et al., "2'-C-Branched ribonucleosides. 2. Synthesis of 2'-C-beta-trifluoromethyl pyrimidine ribonucleosides," Org. Lett., vol. 3, 2001, pp. 1025-1028.	
	C78	LIN, T.S., et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," Tetrahedron Letters, 51(4): 1055-1068 (1995).	
	C79	LOPEZ APARICIO, F.J., et al., "Synthesis of Saccarinic Acid Derivatives," Carbohydrate Res., 129:99 (1984).	
	C80	LOPEZ-HERRERA, F.J., et al., "A New Synthesis of 2-C Methyl-D-Ribono-1, 4-Lactone and the C-(C-13 Fragment of Methynolide," J. Carbohydrate Chemistry, 13(5): 767-775 (1994).	
	C81	MAGA, Giovanni, et al., Lack of stereospecificity of suid pseudorabies virus thymidine kinase," Biochem. J., 294(2): 381-385 (1993).	
	C82	MAHMOUDIAN, M., et al., "A Versatile Procedure for the Generation of Nucleoside 5'-Carboxylic Acids Using Nucleoside Oxidase," Tetrahedron, Elsevier Science Publishers Amsterdam, NL, vol. 54, no. 28, 8171-8182 July 9, 1998.	
	C83	MANSOUR, T.S., et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) Vol. 6, No. 1, pp. 1.	

LAI-301713v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	C84	MARKLAND W., et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy, April 2000, Vol. 44, No. 4, pp. 859-866.	
	C85	McFARLIN, et al., J. Am. Chem. Soc. 1958, 80, 5372-76.	
	C86	MILES, et al., "Circular Dichroism of Nucleoside Derivatives. IX. Vicinal Effects on the Circular Dichroism of Pyrimidine Nucleosides," J. Am. Chem. Soc. 92(13): 3872-3881 (1970).	
	C87	MOISEYEV, et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases," FEBS Letters (1997), 404(2,3), 169-172	
	C88	MOORE, et al., "Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase," Biochemistry (2002), 41(47), 14066-14075.	
	C89	MURAI, et al., "A synthesis and an x-ray analysis of 2'-C, 3'-C- and 5'-C-methylsanguinamycins," Heterocycles (1992), 33(1), 391-404.	
	C90	NISHIGUCHI, S., et al., "Methods to Detect Substitutions in the Interferon-Sensitivity-Determining Region of Hepatitis C virus 1b for Prediction of Response to Interferon Therapy," Hepatology, January 2001, Vol. 33, No. 1, pp. 241-247.	
	C91	NISHIMURA, T. et al. "Studies on Synthetic Nucleosides. Trimethylsilyl Derivatives of Pyrimidine and Purines," Chemical & Pharmaceutical Bulletin (1964), vol. 12, pp. 352-356.	
	C92	NOVAK, J.J.K. & Sorm, F., "Nucleic Acid Components and Their Analogues. CXX. 2-C-Methyl-D-Ribose and Its Derivatives," Collection Czechoslov. Chem. Commun., 34:857-866 (1969).	
	C93	NOVAK, J.J.K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-Erythro-D-Pentono-1, 4-Lactones," Collection Czechoslov. Chem. Commun., 39:869-882 (1974).	
	C94	OLSEN et al. (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A76)	
	C95	PAGLIARO, L., et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI," Recenti Progressi in Medicina, (2006) Vol. 97, No. 12, pp. 741-750.	
	C96	PIERRA, C., et al., "Comparative Studies of Selected Potential Prodrugs of B-L-dC, A Potent and Selective Anti-HBV Agent," Antiviral Res., 50:A79 (2001), Abstract no. 138.	
	C97	PIERRA, C., et al., "NM 283, and efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," Nucleosides, Nucleotides and Nucleic Acids (2005), 24(5-7), 767-770.	
	C98	PIERRA, C., et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," Journal of Medicinal Chemistry (2006), 49(22), 6614-6620.	
	C99	REIST, et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars," Journal of Organic Chemistry (1962), 27 3279-83.	
	C100	ROBINS, et al., "Purine Nucleosides. XXIX. The Synthesis of 2'-Deoxy-L-adenosine and 2'-Deoxy-L-guanosine and Their [alpha] Anomers," Journal of Organic Chemistry, 35(3), 636-639 (March 1970).	
	C101	RONG, et al., "The Synthesis and Conformation of 2'- and 3'-Hypermethylated Tricyclic Nucleosides and Their Use in the Synthesis of Novel 2'- or 3'-Isomeric 4(7)-Substituted Isoxazolidine-nucleosides," Tetrahedron Vol. 50, No. 16, pp. 4921-4936. (1994).	
	C102	ROQUE-AFONSO, AM, et al., "Performance of TRUGENE hepatitis C virus5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," Journal of Viral Hepatitis, September 2002, Vol. 9, Issue 5, pp. 385-389.	

LAI-3017173v1

EXAMINER  
SIGNATURE

/Louise Humphrey/

DATE CONSIDERED

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./



**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C103	SAKTHIVEL, et al. "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." Synlett (2005), (10), 1586-1590.	
	C104	SAKTHIVEL, et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3-deazaadenosine analogs." Tetrahedron Letters (2005), 46(22), 3883-3887.	
	C105	SALIDINO, R., et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," J. chem. Soc., Perkin Trans. I, 21: 3053-3054 (1994).	
	C106	SANDHU, et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." Drug Metabolism and Disposition (2004), 32(11), 1254-1259	
	C107	SATO, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." Tetrahedron Letters (1980), 21(20), 1971-4.	
	C108	SATO, et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." Bulletin of the Chemical Society of Japan (1983), 56(9), 2680-99.	
	C109	SAVOCHKINA, et al., "Substrate properties of c - methyl nucleoside triphosphates in RNA syntheses catalyzed by e. coli RNA - polymerase" Molecular Biology, 1989, v. 23, no. 6.	
	C110	Scheibler, C., "Ueber das Saccharin und die Saccharinsäure," Chemische Berichte, 13:2212-2217 (1880). In German.	
	C111	Schiff, E.R., "Emerging strategies for pegylated interferon combination therapy," Nature Clinical Practice Gastroenterology and Hepatology. (2007) Vol. 4, No. SUPPL. 1, pp. S17-S21.	
	C112	Schmit, C., et al., "Synthesis of 2'-Deoxy-2' -Alpha-Monofluoromethyl and Trifluoromethylnucleosides," Synlett, Thieme Verlag, Stuttgart, DE, no. 4, 1994, pp. 241-242.	
	C113	Shalaby, et al., "Conformations and Structure Studies of Sugar Lactones in the Solid State. Part 11. The Molecular Structure of a-D-Glucosaccharino-Y-Lactone: 2-C-Mehtyl-D-Ribo-Pentono-1,4-lactone." Carbohydrate Research (1994), 264(2), 191-8.	
	C114	SHI, et al., Synthesis and in vitro Anti-HCV Activity of 8-d- and 1-2'-Deoxy-2'-Fluororibonucleosides, Nucleosides, Nucleotides & Nucleic Acids 2005, Volume 23, Numbers 5-7, pp. 875-879.	
	C115	SHIM, Jae H., "Recent patents on nucleoside and nucleotide inhibitors for HCV," Recetn Patents on Anti-Infective Drug Discovery (2006), 1(3), 323-331.	
	C116	SINKO, et al., Carrier-Mediated Intestinal Absorption of Valacyclovir, the L-Valyl Ester Prodrug of Acyclovir. BIOPHARMACEUTICS & DRUG DISPOSITION 1998, Vol. 19, pp. 209-217.	
	C117	SINKULA et al., "Rationale for design of biologically reversible drug derivatives: prodrugs," J. Pharm. Sci., 1975,64: 181-210	
	C118	Smith, et al., "Synthesis of new 2'-b-C-methyl related tricinibine analogues as anti-HCV agents." Valeant Pharmaceuticals International, Costa Mesa, CA, USA. Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3517-3520.	
	C119	Song, et al., Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevaluation, and hPEPT1-Medicated Transport," Molecular Pharmaceutics (2005), 2(2), 157-167.	
	C120	Sorbera, L.A., et al., "Valopicitabine: anti-hepatitis C virus drug RNA -directed RNA polymerase (NS5B) inhibitor," Drugs of the Future (2006), 31 (4), 320-324.	
	C121	Sowden, J., "The Saccharinic Acids," Adv. Carbohydrate Chem., 12:43-46 (1957).	
	C122	Spardari, et al., "L-Thymidine is Phosphorylated by Herpes Simplex Virus Type 1 Thymidine Kinase and Inhibits Viral Growth." Journal of Medicinal Chemistry, 35(22), 4214-4220 (1992).	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C123	Standing, D.N., et al., "Antiviral Beta-L-Nucleosides Specific for Hepatitis B Virus Infection," <i>Antiviral Chem. &amp; Chemother.</i> , 12 (Suppl. 1): 119-129 (2001).	
	C124	Stuyver, et al., "Ribonucleoside Analogue That Block Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture." <i>Antimicrobial Agents and Chemotherapy</i> , Vol 47, No. 1, Jan. 2003, p. 244-254.	
	C125	Sundberg, et al., <i>Advanced Organic Chemistry</i> , Part b, 1990, pages 232 and 236.	
	C126	Takenuki, et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." <i>Chemical &amp; Pharmaceutical Bulletin</i> (1990), 38(11), 2947-52.	
	C127	Tang, X.-Q., et al., "2'-C-Branches Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-B-Methylcytidine and Their Incorporation into Oligonucleotides." <i>J. Org. Chem.</i> , 64(3): 747-754 (1999).	
	C128	The Merck Index, 12th edition, 1996, Page 275	
	C129	Tronchet, et al., "72. Synthèse et désamination enzymatique des C-hydroxyméthyl-3'-et C-méthyl-3'-β-D-xylofuranosyl-9-adenines." <i>Helv. Chim. Acta</i> , vol. 62, 1979, pp. 689-695.	
	C130	Tyrsted, G., et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs." <i>Biochem. Biophys. Acta.</i> , 155(2): 619-622 (February 26, 1968).	
	C131	Velazquez, et al., "Synthesis of [1-3',5'-bis-O-(tert-butyl(dimethylsilyl)-beta-D-arabino- and beta-D-ribofuranosyl] cytosine]-2'-spiro-5''-(4''-amino-1'',2'',-oxathiole-2''),2''-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T." <i>Tetrahedron</i> , vol. 50, 1994, pp. 11013-11022.	
	C132	Verri, A., et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of B-L-deoxycytidine analogs as antineoplastic and antiviral agents." <i>Molecular Pharmacology</i> , 51(1): 132-138 (January 1997).	
	C133	Verri, a., et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues." <i>Biochem. J.</i> , 328(1): 317-320 (November 15, 1997).	
	C134	Von Buren, et al., "Branched oligodeoxynucleotides: automated synthesis and triple helical hybridization studies." <i>Tetrahedron</i> (1995), 51(31), 8491-506.	
	C135	Von Janta-Lipinski, M., et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified B-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular SNA Polymerases a, B, y, d and E Nor HIV-1 Reverse Transcriptase." <i>J. Medicinal Chemistry</i> , 41(12): 2040-2046 (May 21, 1998).	
	C136	Wagner, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides." <i>J. Org. Chem.</i> , 39(1):24-30 (1974).	
	C137	WALTON et al., "Branched-chain sugar nucleosides. A new type of biologically active nucleoside," <i>J. Am. Chem. Soc.</i> , 88(19): 4524-25 (1966)	
	C138	Whistler, R. L., and BeMiller, J.N., "[118] 'a'-D-Glucosaccharin-1,4-Lactone." <i>Methods in Carbohydrate Chemistry</i> , 2:484-485 (1963).	
	C139	Wohnsland, A., et al., "Viral determinants of resistance to treatment in patients with hepatitis C," <i>Clinical Microbiology reviews</i> , (2007) Vol. 20, No. 1, pp. 23-38.	
	C140	Wolf, et al., "New 2'-C-Branches Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity," <i>Synthesis</i> , Georg Thieme Verlag, Stuttgart, DE, no. 8, August 1992 (1992-08), pp. 773-778.	
	C141	WU, et al., Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. <i>Current Drug Targets - Infectious Disorders</i> 2003, Vol. 3, p. 207-219.	
	C142	ZEDECK et al., "Inhibition of the steroid induced synthesis of Δ5-3-ketosteroid isomerase in <i>Pseudomonas</i>	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		testosteroni by a new purine deoxyribonucleoside analog: 6-chloro-8-aza-9-cyclopentylpurine," Mol. Phys., 3(4):386-95 (1967)	
	C143	Zemlicka, J., et al. "Aminoacyl Derivatives of Nucleosides, Nucleotides, and polynucleotides. VIII. The Preparation of 2'(3')-O-L-Phenylalanyluridine, -cytidine, - Adenosine, -inosine, -guanosine and 2'-Deoxy-3' O-L-Phenylalanyladenosine," Collection Czechoslov. Chem. Commun. 1969, Vol. 43, No. 13, 3755-3767.	
	C144	Zemlicka, J., et al., "Substrate Specificity of Ribosomal Peptidyltransferase. Peditidyltransferase. Effect of Modifications in the Heterocyclic, Carbohydrate and Amino Acid Moiety of 2'(3')-O-L-Phenyladenosine," Biochemistry, December 2, 1975, Vol. 14, No. 24, 5239-5249.	
	C145	ZHOU, et al., Pharmacokinetics and pharmacodynamics of valopicitabine. Journal of Hepatology 2005, Vol. 42 (Suppl. 2), p. 229.	
	C146	Zinchenko, et al., "2', 3' & 5' - uridine methyl derivatives in microbiological translocation." Doklady Akad Nauk v.297(3), pp. 731-734 (1987).	
	C147	Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosphorases in whole cells of e. coli" Biopolymers & a cell, 1988, v. 4, No. 6.	
	C148	Zinchenko, et al., "Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of Escherichia Coli." Nucleic Acids Research, Symposium Series No. 18, 1987, pp. 137-140.	
	C149	Office Action dated October 1, 2003 from application number 09/863,816.	
	C150	Notice of Allowance dated June 23, 2004 from application number 09/863,816.	
	C151	Office Action dated August 27, 2003 from application number 09/864,078.	
	C152	Notice of Allowance dated February 19, 2004 from application number 09/864,078.	
	C153	Notice of Allowance dated May 17, 2005 from application number 10/602,135.	
	C154	Office Action dated April 5, 2005 from application number 10/602,135.	
	C155	Notice of Allowance dated March 9, 2006 from application number 10/602,136.	
	C156	Office Action dated July 28, 2006 from application number 10/602,142.	
	C157	Office Action dated September 20, 2007 from application number 10/602,142.	
	C158	Office Action dated December 10, 2008 from application number 10/602,142.	
	C159	Office Action dated November 15, 2005 from application number 10/602,142.	
	C160	Office Action dated March 29, 2007 from application number 10/602,142.	
	C161	Office Action dated February 26, 2008 from application number 10/602,142.	
	C162	Office Action dated May 30, 2006 from application number 10/602,691.	
	C163	Office Action dated August 22, 2007 from application number 10/602,691.	
	C164	Office Action dated October 7, 2008 from application number 10/602,691.	
	C165	Office Action dated December 29, 2006 from application number 10/602,691.	

LAJ-3017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C166	Office Action dated November 7, 2005 from application number 10/602,691.	
	C167	Office Action dated February 26, 2008 from application number 10/602,691.	
	C168	Notice of Allowance dated December 28, 2005 from application number 10/602,692.	
	C169	Office Action dated April 5, 2005 from application number 10/602,692.	
	C170	Notice of Allowance dated December 27, 2005 from application number 10/602,693.	
	C171	Office Action dated April 6, 2005 from application number 10/602,693.	
	C172	Notice of Allowance dated December 27, 2005 from application number 10/602,694.	
	C173	Office Action dated April 6, 2005 from application number 10/602,694.	
	C174	Office Action dated September 10, 2004 from application number 10/602,976.	
	C175	Office Action dated May 19, 2005 from application number 10/602,976.	
	C176	Notice of Allowance dated October 13, 2005 from application number 10/602,976.	
	C177	Office Action dated 8/15/2006 from application number 10/608,907.	
	C178	Office Action dated 5/31/2007 from application number 10/608,907.	
	C179	Office Action dated 1/28/2008 from application number 10/608,907.	
	C180	Office Action dated November 26, 2008 from application number 10/608,907.	
	C181	Notice of Allowance dated April 7, 2009 from application number 10/608,907.	
	C182	Office Action dated August 2, 2006 from application number 10/609,298.	
	C183	Office Action dated July 10, 2008 from application number 10/609,298.	
	C184	Notice of Allowance dated April 7, 2009 from application number 10/609,298.	
	C185	Office Action dated October 5, 2005 from application number 11/005,440.	
	C186	Office Action dated December 5, 2006 from application number 11/005,440.	
	C187	Office Action dated June 13, 2007 from application number 11/005,440.	
	C188	Office Action dated October 16, 2007 from application number 11/005,440.	
	C189	Office Action dated August 21, 2006 from application number 11/005,441.	
	C190	Notice of Allowance dated June 22, 2007 from application number 11/005,441.	
	C191	Notice of Allowance dated January 8, 2008 from application number 11/005,441.	
	C192	Office Action dated August 7, 2006 from application number 11/005,442.	

LA1-3017173v1

EXAMINER  
SIGNATURE

/Louise Humphrey/

DATE CONSIDERED

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C193	Office Action dated May 16, 2007 from application number 11/005,442.	
	C194	Office Action dated November 28, 2007 from application number 11/005,442.	
	C195	Office Action dated October 5, 2005 from application number 11/005,443	
	C196	Office Action dated March 12, 2007 from application number 11/005,443	
	C197	Advisory Action dated August 8, 2007 from application number 11/005,443	
	C198	Office Action dated September 5, 2008 from application number 11/005,443	
	C199	Office Action dated October 12, 2005 from application number 11/005,444	
	C200	Office Action dated December 5, 2006 from application number 11/005,444	
	C201	Office Action dated June 13, 2007 from application number 11/005,444	
	C202	Office Action dated October 9, 2007 from application number 11/005,444	
	C203	Office Action dated October 6, 2008 from application number 11/005,444	
	C204	Office Action dated October 6, 2006 from application number 11/005,445	
	C205	Office Action dated February 26, 2008 from application number 11/005,445	
	C206	Office Action dated October 7, 2008 from application number 11/005,445	
	C207	Office Action dated July 17, 2008 from application number 11/005,445	
	C208	Notice of Allowance dated March 30, 2009 from application number 11/005,445.	
	C209	Office Action dated October 5, 2005 from application number 11/005,446	
	C210	Office Action dated December 5, 2006 from application number 11/005,446	
	C211	Office Action dated August 20, 2007 from application number 11/005,446	
	C212	Office Action dated March 17, 2008 from application number 11/005,446	
	C213	Notice of Allowance dated October 11, 2006 from application number 11/005,447	
	C214	Notice of Allowance dated February 12, 2007 from application number 11/005,447	
	C215	Notice of Allowance dated August 22, 2007 from application number 11/005,447	
	C216	Office Action dated October 12, 2005 from application number 11/005,466	
	C217	Office Action dated November 20, 2006 from application number 11/005,466	
	C218	Office Action dated June 13, 2007 from application number 11/005,466	
	C219	Office Action dated October 9, 2007 from application number 11/005,466	

LAJ-2017173v1

**EXAMINER  
SIGNATURE**

/Louise Humphrey/

**DATE CONSIDERED**

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C220	Office Action dated August 18, 2006 from application number 11/005,467	
	C221	Notice of Allowance dated August 22, 2007 from application number 11/005,467	
	C222	Office Action dated September 26, 2006 from application number 11/005,468	
	C223	Office Action dated June 14, 2007 from application number 11/005,468	
	C224	Office Action dated October 2, 2007 from application number 11/005,468	
	C225	Office Action dated October 5, 2006 from application number 11/005,469	
	C226	Office Action dated July 18, 2007 from application number 11/005,469	
	C227	Office Action dated March 24, 2008 from application number 11/005,469	
	C228	Notice of Allowance dated October 12, 2006 from application number 11/005,470	
	C229	Notice of Allowance dated March 7, 2007 from application number 11/005,470	
	C230	Notice of Allowance dated August 22, 2007 from application number 11/005,470	
	C231	Office Action dated July 18, 2007 from application number 11/005,471	
	C232	Office Action dated February 28, 2008 from application number 11/005,471	
	C233	Office Action dated October 12, 2005 from application number 11/005,472	
	C234	Office Action dated December 5, 2006 from application number 11/005,472	
	C235	Office Action dated June 13, 2007 from application number 11/005,472	
	C236	Office Action dated October 9, 2007 from application number 11/005,472	
	C237	Office Action dated November 25, 2005 from application number 11/005,473	
	C238	Notice of Allowance dated August 8, 2006 from application number 11/005,473	
	C239	Office Action dated October 2, 2009 from application number 11/516,928.	

LA1-3017173v1

EXAMINER  
SIGNATURE

/Louise Humphrey/

DATE CONSIDERED

06/19/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.H./